| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anja Kunze, Robert Meissner, Serena Brando, Philippe Renau. Co-pathological connected primary neurons in a microfluidic device for Alzheimer studies. Biotechnology and bioengineering. vol 108. issue 9. 2011-11-15. PMID:21391208. |
oa is a phosphatase inhibitor that induces hyperphosphorylation of tau proteins, a major hallmark in alzheimer disease. |
2011-11-15 |
2023-08-12 |
Not clear |
| Lilla Reiniger, Ana Lukic, Jacqueline Linehan, Peter Rudge, John Collinge, Simon Mead, Sebastian Brandne. Tau, prions and Aβ: the triad of neurodegeneration. Acta neuropathologica. vol 121. issue 1. 2011-11-14. PMID:20473510. |
it also discusses similarities between prion disease and alzheimer's disease: mechanisms of amyloid formation, neurotoxicity, pathways involved in triggering tau phosphorylation, links to cell cycle pathways and neuronal apoptosis. |
2011-11-14 |
2023-08-12 |
Not clear |
| Claire J Garwood, Jonathan D Cooper, Diane P Hanger, Wendy Nobl. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Frontiers in psychiatry. vol 1. 2011-11-10. PMID:21423446. |
alzheimer's disease (ad) is characterized by the extracellular deposition of β-amyloid in senile plaques, the intraneuronal accumulation of hyperphosphorylated tau aggregates as neurofibrillary tangles, and progressive neuronal loss leading to the onset of dementia. |
2011-11-10 |
2023-08-12 |
mouse |
| Claire J Garwood, Jonathan D Cooper, Diane P Hanger, Wendy Nobl. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Frontiers in psychiatry. vol 1. 2011-11-10. PMID:21423446. |
recently, we demonstrated that minocycline reduces the development of abnormal tau species in the htau mouse model of alzheimer's disease. |
2011-11-10 |
2023-08-12 |
mouse |
| Ana Martinez, Carmen Gil, Daniel I Pere. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. International journal of Alzheimer's disease. vol 2011. 2011-11-10. PMID:21760986. |
glycogen synthase kinase 3 (gsk-3), a proline/serine protein kinase ubiquitously expressed and involved in many cellular signaling pathways, plays a key role in the pathogenesis of alzheimer's disease (ad) being probably the link between β-amyloid and tau pathology. |
2011-11-10 |
2023-08-12 |
Not clear |
| Diane P Hanger, Wendy Nobl. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. International journal of Alzheimer's disease. vol 2011. 2011-11-10. PMID:21776376. |
highly phosphorylated forms of tau are deposited in the brain in a range of neurodegenerative disorders including alzheimer's disease, progressive supranuclear palsy, and frontotemporal lobar degeneration associated with pick bodies. |
2011-11-10 |
2023-08-12 |
Not clear |
| Charlotte Delay, Sébastien S Héber. MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues. International journal of Alzheimer's disease. vol 2011. 2011-11-10. PMID:21826259. |
evidence from clinical trials as well as from studies performed in animal models suggest that both amyloid and tau pathologies function in concert with other factors to cause the severe neurodegeneration and dementia in alzheimer's disease (ad) patients. |
2011-11-10 |
2023-08-12 |
mouse |
| José L Vázquez-Higuera, Ignacio Mateo, Pascual Sánchez-Juan, Eloy Rodríguez-Rodríguez, Ana Pozueta, Miguel Calero, José L Dobato, Ana Frank-García, Fernando Valdivieso, José Berciano, Maria J Bullido, Onofre Combarro. Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk. BMC research notes. vol 4. 2011-11-10. PMID:21899770. |
genetic variation in the tau protein phosphatase-2a pathway is not associated with alzheimer's disease risk. |
2011-11-10 |
2023-08-12 |
Not clear |
| Miguel Medina, Juan Jose Garrido, Francisco G Wandosel. Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Frontiers in molecular neuroscience. vol 4. 2011-11-10. PMID:22007157. |
different neurodegenerative diseases including frontotemporal dementia, progressive supranuclear palsy, and alzheimer's disease, present prominent tau pathology such as tau hyperphosphorylation and aggregation and are collectively referred to as tauopathies. |
2011-11-10 |
2023-08-12 |
human |
| Yaroslau Compta, Mario Ezquerra, Esteban Muñoz, Eduardo Tolosa, Francesc Valldeoriola, Jose Rios, Ana Cámara, Manel Fernández, Maria Teresa Buongiorno, Maria Jose Mart. High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease. Neuroscience letters. vol 487. issue 2. 2011-11-08. PMID:20951764. |
cerebrospinal fluid (csf) tau and phospho-tau levels have been associated with certain tau gene variants and low csf amyloid-β (aβ) levels in alzheimer disease (ad), constituting potential biomarkers of molecular mechanisms underlying neurodegeneration. |
2011-11-08 |
2023-08-12 |
Not clear |
| Dennis J Selko. Alzheimer's disease. Cold Spring Harbor perspectives in biology. vol 3. issue 7. 2011-11-07. PMID:21576255. |
we will discuss how elucidating the genotype-to-phenotype relationships of familial forms of alzheimer's disease has highlighted the importance of the misfolding and altered proteostasis of two otherwise soluble proteins, amyloid β-protein and tau, suggesting mechanism-based therapeutic targets that have led to clinical trials. |
2011-11-07 |
2023-08-12 |
human |
| Katarzyna M Osiecka, Hanna Nieznanska, Krzysztof J Skowronek, Jolanta Jozwiak, Krzysztof Nieznansk. Tau inhibits tubulin oligomerization induced by prion protein. Biochimica et biophysica acta. vol 1813. issue 10. 2011-11-07. PMID:21763357. |
since elevated phosphorylation of tau leading to a loss of its function is observed in alzheimer disease and related tauopathies, our results point at a possible molecular link between these neurodegenerative disorders and tses. |
2011-11-07 |
2023-08-12 |
Not clear |
| Yuanjie Sun, Nam-Ho Kim, Haijie Yang, Seung-Hyuk Kim, Sung-Oh Hu. Lysophosphatidic acid induces neurite retraction in differentiated neuroblastoma cells via GSK-3β activation. Molecules and cells. vol 31. issue 5. 2011-11-04. PMID:21499833. |
alterations in cell morphology, including neurite retraction, in neurodegenerative disorders such as alzheimer's disease involve hyperphosphorylation of the cytoskeletal protein tau. |
2011-11-04 |
2023-08-12 |
Not clear |
| John Koren, Umesh K Jinwal, Zachary Davey, Janine Kiray, Karthik Arulselvam, Chad A Dicke. Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathies. Molecular neurobiology. vol 44. issue 1. 2011-11-04. PMID:21523562. |
the hsp90-associated cis-trans peptidyl-prolyl isomerase--fk506 binding protein 51 (fkbp51)--was recently found to co-localize with the microtubule (mt)-associated protein tau in neurons and physically interact with tau in brain tissues from humans who died from alzheimer's disease (ad). |
2011-11-04 |
2023-08-12 |
Not clear |
| Anne M Fagan, Leslie M Shaw, Chengjie Xiong, Hugo Vanderstichele, Mark A Mintun, John Q Trojanowski, Els Coart, John C Morris, David M Holtzma. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Archives of neurology. vol 68. issue 9. 2011-11-02. PMID:21555603. |
comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying alzheimer disease amyloid plaque pathology. |
2011-11-02 |
2023-08-12 |
Not clear |
| Isabelle Landrieu, Caroline Smet-Nocca, Laziza Amniai, Justin Vijay Louis, Jean-Michel Wieruszeski, Jozef Goris, Veerle Janssens, Guy Lippen. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PloS one. vol 6. issue 6. 2011-11-02. PMID:21731772. |
molecular implication of pp2a and pin1 in the alzheimer's disease specific hyperphosphorylation of tau. |
2011-11-02 |
2023-08-12 |
Not clear |
| Isabelle Landrieu, Caroline Smet-Nocca, Laziza Amniai, Justin Vijay Louis, Jean-Michel Wieruszeski, Jozef Goris, Veerle Janssens, Guy Lippen. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PloS one. vol 6. issue 6. 2011-11-02. PMID:21731772. |
tau phosphorylation and dephosphorylation regulate in a poorly understood manner its physiological role of microtubule stabilization, and equally its integration in alzheimer disease (ad) related fibrils. |
2011-11-02 |
2023-08-12 |
Not clear |
| Richard J O'Brien, Philip C Won. Amyloid precursor protein processing and Alzheimer's disease. Annual review of neuroscience. vol 34. 2011-10-25. PMID:21456963. |
alzheimer's disease (ad), the leading cause of dementia worldwide, is characterized by the accumulation of the β-amyloid peptide (aβ) within the brain along with hyperphosphorylated and cleaved forms of the microtubule-associated protein tau. |
2011-10-25 |
2023-08-12 |
Not clear |
| Jedsada Thaweepoksomboon, Vorapun Senanarong, Niphon Poungvarin, Tipa Chakorn, Nopwan Siwasariyanon, Lerdchai Washirutmangkur, Suthipol Udompunthuru. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. vol 94 Suppl 1. 2011-10-25. PMID:21721431. |
assessment of cerebrospinal fluid (csf) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total tau protein in patients with alzheimer's disease (ad) and other dementia at siriraj hospital, thailand. |
2011-10-25 |
2023-08-12 |
Not clear |
| Danielle Frost, Bessie Meechoovet, Tong Wang, Stephen Gately, Marco Giorgetti, Irina Shcherbakova, Travis Dunckle. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PloS one. vol 6. issue 5. 2011-10-24. PMID:21573099. |
β-carboline compounds, including harmine, inhibit dyrk1a and tau phosphorylation at multiple alzheimer's disease-related sites. |
2011-10-24 |
2023-08-12 |
Not clear |